Rosetta Genomics Ltd. appointed Kevin Watson to the newly established role of Director, Reimbursement-Managed Care. Mr. Watson joins Rosetta Genomics from competing molecular diagnostics company, bioTheranostics, where for two years he was the Director of Reimbursement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% | -.--% | -.--% |
2018 | Genoptix, Inc. cancelled the acquisition of Rosetta Genomics Ltd.. | CI |
2018 | Rosetta Genomics Ltd.(NasdaqCM:ROSG) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 592 | |
+48.64% | 56.65B | |
-6.44% | 39.44B | |
+37.29% | 39.03B | |
+14.28% | 26.75B | |
-11.17% | 26.86B | |
-21.40% | 19.03B | |
+25.64% | 12.26B | |
+0.96% | 12.28B | |
+27.04% | 12.04B |
- Stock Market
- Equities
- ROSGQ Stock
- News Rosetta Genomics Ltd.
- Rosetta Genomics Ltd. Appoints Kevin Watson as Director, Reimbursement-Managed Care